Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from Analysts

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has earned a consensus rating of "Buy" from the six ratings firms that are currently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $23.80.

A number of research firms have issued reports on LXEO. Chardan Capital increased their price target on Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Royal Bank of Canada reissued an "outperform" rating and set a $24.00 target price on shares of Lexeo Therapeutics in a research note on Tuesday, January 21st. Leerink Partners decreased their price target on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an "outperform" rating for the company in a research note on Wednesday, November 13th. Finally, HC Wainwright upped their price objective on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the company a "buy" rating in a report on Thursday, November 14th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Allostery Investments LP bought a new stake in shares of Lexeo Therapeutics during the fourth quarter worth about $33,000. China Universal Asset Management Co. Ltd. acquired a new position in Lexeo Therapeutics during the 4th quarter valued at about $46,000. BNP Paribas Financial Markets increased its holdings in Lexeo Therapeutics by 184.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company's stock worth $50,000 after purchasing an additional 3,591 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in shares of Lexeo Therapeutics in the fourth quarter worth approximately $69,000. Finally, SG Americas Securities LLC bought a new position in shares of Lexeo Therapeutics in the fourth quarter valued at approximately $72,000. Institutional investors and hedge funds own 60.67% of the company's stock.

Remove Ads

Lexeo Therapeutics Trading Up 1.5 %

Shares of Lexeo Therapeutics stock traded up $0.04 on Friday, hitting $2.66. 398,047 shares of the company's stock traded hands, compared to its average volume of 355,327. The company has a market capitalization of $87.96 million, a price-to-earnings ratio of -0.84 and a beta of 3.85. The company has a fifty day moving average of $4.90 and a two-hundred day moving average of $7.30. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. Lexeo Therapeutics has a one year low of $2.32 and a one year high of $19.50.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.